Sterile compounding remains under close regulatory scrutiny: in FY2025, FDA conducted 42 inspections of 503B outsourcing facilities, up from 33 in FY2024, and 17 were reinspections a clear signal that unresolved quality risks can quickly return to the inspection agenda. USP 797 Compliance therefore requires more than a cleanroom and written procedures; facilities must control aseptic technique, personnel competency, environmental monitoring, and beyond-use dates with clear, traceable evidence.
Moreover, effective pharma quality management connects these controls and helps teams identify gaps before they affect sterile preparations. This guide explains the current requirements and the evidence facilities should keep ready for inspection.
Table of Contents
What Is USP 797 Compliance?
USP 797 Compliance means following the required quality and practice standards for preparing compounded sterile preparations safely and consistently. It covers trained personnel, controlled facilities, aseptic processes, environmental monitoring, documentation, and sterility controls. In addition, facilities must demonstrate that staff follow procedures correctly and that cleanroom conditions remain within defined limits. Therefore, strong compliance helps reduce contamination risks, protect patients, and provide clear evidence during inspections.
Why Sterile Compounding Standards Matter for Regulatory Compliance
Sterile compounding standards protect patients by reducing the risk of microbial contamination, preparation errors, and other quality failures that can make compounded sterile preparations unsafe. Therefore, regulators expect facilities to control cleanroom conditions, aseptic practices, personnel competency, and environmental monitoring consistently. However, written SOPs alone do not prove compliance. Inspectors also examine how staff perform each process in practice, how teams document deviations, and whether records support effective control. As a result, strong USP 797 Compliance depends on both well-designed procedures and reliable day-to-day execution.
Four Controls That Determine Sterile Compounding Readiness
Sterile compounding readiness depends on more than written procedures. Facilities need effective controls that work consistently across the compounding environment, personnel practices, monitoring activities, and sterility assurance. Together, these four areas show whether a facility can maintain USP 797 Compliance in daily operations and during inspections.
The following four control areas provide a practical framework for evaluating sterile compounding readiness:
- Cleanroom Design and Engineering Controls (PDF)
- Personnel Training, Garbing, and Competency (PDF)
- Environmental Monitoring and Aseptic Technique (PDF)
- Beyond-Use Dates and Sterility Assurance (PDF)
The infographic below highlights four core USP 797 controls that support safe sterile compounding and inspection readiness.
Cleanroom Design and Engineering Controls (PDF)
Cleanroom controls manage airflow, filtration, pressure, and contamination risks during sterile compounding.
Download FDA Guide to Cleanroom Design and Engineering Controls for Aseptic Processing Here
Personnel Training, Garbing, and Competency (PDF)
Staff must demonstrate proper garbing, aseptic technique, and competency before sterile compounding.
Download USP 797 Personnel Training, Garbing, and Competency Requirements Here
Environmental Monitoring and Aseptic Technique (PDF)
Environmental monitoring and aseptic technique help detect and reduce contamination risks.
Download FDA Environmental Monitoring Guide for Sterile Compounding Facilities Here
Beyond-Use Dates and Sterility Assurance (PDF)
Beyond-use dates depend on sterility, preparation methods, storage conditions, and testing.
Download USP 797 Beyond-Use Dates and Sterility Assurance Guide Here
How USP 797 CSP Categories Change Compliance Requirements
Under USP 797 Compliance, Category 1, Category 2, and Category 3 CSPs follow different controls based mainly on the compounding environment, storage time, and measures used to control microbial risk. As facilities move from Category 1 to Category 3, they can assign longer beyond-use dates; however, they must also strengthen environmental monitoring, personnel qualification, sterility assurance, and documentation. Therefore, choosing the correct CSP category directly affects both daily compounding practices and inspection readiness.
The table below compares the key compliance expectations for each USP 797 CSP category.
| CSP Category | Compounding Environment | BUD Approach | Additional Controls | Typical Inspection Evidence |
|---|---|---|---|---|
|
Category 1 |
ISO 5 PEC; may operate within an unclassified SCA |
Maximum 12 hours at room temperature or 24 hours refrigerated |
Core garbing, aseptic technique, cleaning, certification, and monitoring controls |
Area certification, competency records, cleaning logs, compounding records, BUD documentation |
|
Category 2 |
ISO 5 PEC within a controlled cleanroom environment |
BUD depends on starting-component sterility, compounding method, sterility testing, and storage; limits can reach 45 days room temperature, 60 days refrigerated, or 90 days frozen |
Stronger facility controls; sterility testing when required for the assigned BUD |
Cleanroom certification, environmental monitoring, personnel qualification, sterility-test records, batch and BUD records |
|
Category 3 |
Controlled cleanroom environment meeting Category 2 requirements |
Extended BUDs can reach 90 days room temperature, 120 days refrigerated, or 180 days frozen, depending on processing and testing |
Sterile garb, more frequent monitoring and competency testing, increased sporicidal use, sterility testing, applicable endotoxin testing, and stability support |
Sterility and stability data, enhanced monitoring trends, personnel records, cleaning records, release-testing results, and complete batch documentation |
USP specifically requires more extensive controls for Category 3 CSPs, including more frequent environmental monitoring and personnel qualification, sterile garbing, stability determination, and sterility testing.
The infographic below compares USP 797 Category 1, 2, and 3 CSPs, from compounding environments and BUDs to required controls and inspection evidence.
How to Prepare for a USP 797 Inspection
A successful USP 797 inspection starts with evidence that teams can retrieve quickly and explain clearly. Quality and pharmacy teams should organize training records, environmental monitoring data, cleaning logs, competency results, compounding records, and deviation investigations before inspectors request them. In addition, teams should confirm that daily practices match written procedures and that records demonstrate consistent control over time. Therefore, strong inspection readiness requires facilities to prove that sterile compounding controls work effectively in daily practice, not only on paper.
Final Words
Recent inspection data shows why sterile compounding readiness must remain continuous: NABP analyzed 213 pharmacy inspections and found only 80% full compliance for aseptic manipulation competency documentation in sterile compounding. Therefore, strong USP 797 Compliance requires teams to maintain training, monitoring, documentation, and corrective actions every day, not only when an inspection approaches.
Qualification and Validation for GMP Systems
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
FAQ
Inspectors commonly find weaknesses in personnel competency, environmental monitoring, cleaning records, aseptic practices, and documentation. Sterile compounding teams should verify both records and actual execution.
Personnel must complete initial qualification and recurring competency assessments according to applicable USP 797 requirements. Facilities should keep current records for garbing, aseptic technique, and related sterile compounding tasks.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.